Skip to content
Markets News
Stocks1 min read

Bayer’s Roundup Verdict Meets a Key Test in Quarterly Results

Makkler Newsroom
November 2, 2026 · Based on reporting by finanzen.net

A jury rejected three glyphosate claims, while investors await Bayer’s quarterly results and a decision on its proposed settlement.

Key takeaways

  • A St. Louis jury unanimously rejected glyphosate claims brought by three women.
  • Analysts expect Bayer’s third-quarter adjusted EBITDA to fall 6% to €1.43 billion.

A St. Louis jury unanimously rejected glyphosate claims brought by three women against Bayer subsidiary Monsanto. Bayer shares traded at €49.72, down 1.7% from the previous close, as of 10:00 UTC Monday.

The case was the first glyphosate trial since the U.S. Supreme Court in June 2026 excluded claims based on allegedly missing cancer warnings. The women instead argued that Roundup had a fundamental product defect and that Monsanto was negligent.

Around 65,000 cases remain pending, according to Bloomberg. A Missouri judge still needs to give final approval to Bayer’s proposed $7.25 billion settlement, which received preliminary approval in March.

Analysts expect third-quarter revenue of €9.92 billion, up from €9.66 billion a year earlier. They forecast adjusted EBITDA falling 6% to €1.43 billion and adjusted earnings per share declining to €0.36 from €0.49.

Analysts cited by Dow Jones Newswires expect Crop Science margins to face pressure from production costs, drought and pricing. Bayer is due to report its third-quarter results on Tuesday.

Topics
BAYNMonsanto
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.